2171 — CARsgen Therapeutics Holdings Share News
0.000.00%
Last trade - 00:00- HK$6.66bn
- HK$5.18bn
- CNY125.66m
Brief: CARsgen Therapeutics Says Do Not Hold Cash Deposits Or Lines Of Credit With Silicon Valley Bank
Brief: Carsgen Therapeutics Executes Collaboration Agreement With F. Hoffmann-La Roche
Brief: Carsgen Therapeutics Says Collaboration Agreement For Zevorcabtagene- Autoleucel
Brief: CARsgen Presents Data From China Study Of Cancer Therapy At 2022 ASH Annual Meeting
Brief: GIC Private Ltd's Long Position In Hong Kong Shares Of Carsgen Therapeutics Falls To 5.83% - Filing
Brief: Carsgen Announces NDA Acceptance Of BCMA Car T Zevor-Cel (Ct053) By China NMPA
China's CARsgen jumps most in near 10 weeks on new drug application
Brief: Carsgen Therapeutics Says NMPA Accepted NDA For Zevorcabtagene Autoleucel
Brief: CARsgen Releases First Clinical Batch Of CAR T Cells From North Carolina Facility
Brief: Carsgen Therapeutics Holdings Says HY Adjusted Net Loss RMB352.9 Mln
Brief: CARsgen Therapeutics Names Hua Jiang As Executive Director
Brief: Carsgen Therapeutics Sees Decrease Of Net Loss For Six Months
Brief: GIC Private Ltd's Long Position In Ordinary Shares Of CARsgen Therapeutics Falls To 8.99% - Filing
Brief: GIC Private Limited's Long Position In Ordinary Shares Of CARsgen Therapeutics Falls - Filing
Brief: GIC Private Ltd's Long Position In Ordinary Shares Of CARsgen Therapeutics Falls To 10.96% - Filing
Brief: CARsgen Announces First Patient Enrollment In The Confirmatory Phase II Clinical Trial Of Ct041 In China
Brief: Carsgen Therapeutics Says FY Net Loss RMB4.74 Bln Vs Loss Of RMB1.06 Bln
Brief: Carsgen Therapeutics Says It Has Been Selected As An Eligible Stock In Respective Stock Lists Of Shanghai-Hong Kong Stock Connect Programme
Brief: Claudin18.2 CAR T Cells (Ct041) Receives Approval To Initiate Confirmatory Phase II Clinical Trial In China